NAMS: NewAmsterdam Pharma Company N.V. Stocks News on April 4, 2025

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

NAMS

Investor's Business Daily

4 days ago

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAMS

GlobeNewswire

4 days ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAMS

Simply Wall St.

a month ago

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NAMS

Simply Wall St.

a month ago

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NAMS

GlobeNewswire

a month ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAMS

GlobeNewswire

a month ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAMS

Simply Wall St.

2 months ago

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMS

GlobeNewswire

2 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NAMS

GlobeNewswire

2 months ago

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NAMS

GlobeNewswire

3 months ago

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NAMS

GlobeNewswire

3 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NAMS

GlobeNewswire

4 months ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAMS

GlobeNewswire

4 months ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NAMS

Investor's Business Daily

4 months ago

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NAMS

Investor's Business Daily

4 months ago

NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAMS

GlobeNewswire

4 months ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NAMS

GlobeNewswire

4 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NAMS

GlobeNewswire

4 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

NAMS

TipRanks

4 months ago

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study

NAMS

Investor's Business Daily

4 months ago

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

NAMS

GlobeNewswire

4 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NAMS

GlobeNewswire

5 months ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NAMS

Simply Wall St.

5 months ago

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NAMS

GlobeNewswire

5 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NAMS

GlobeNewswire

5 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

NAMS

GlobeNewswire

5 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Three Undervalued Small Caps In United States With Insider Buying To Consider

NAMS

Simply Wall St.

6 months ago

Three Undervalued Small Caps In United States With Insider Buying To Consider

Insider Buying Highlights These 3 Undervalued Small Caps In United States

NAMS

Simply Wall St.

6 months ago

Insider Buying Highlights These 3 Undervalued Small Caps In United States

NAMS

GlobeNewswire

6 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMS

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 10/02/2024

3 Undervalued Small Caps In United States With Insider Buying

NAMS

Simply Wall St.

6 months ago

3 Undervalued Small Caps In United States With Insider Buying

NAMS

Simply Wall St.

7 months ago

While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership

NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations

NAMS

Simply Wall St.

8 months ago

NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NAMS

GlobeNewswire

8 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NAMS

GlobeNewswire

8 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMS

Simply Wall St.

8 months ago

NewAmsterdam Pharma (NASDAQ:NAMS) Is In A Good Position To Deliver On Growth Plans

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations

NAMS

Investor's Business Daily

8 months ago

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

NAMS

GlobeNewswire

8 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NAMS

GlobeNewswire

8 months ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NAMS

GlobeNewswire

9 months ago

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NAMS

GlobeNewswire

9 months ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NAMS

GlobeNewswire

9 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office

NAMS

GlobeNewswire

10 months ago

NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

NAMS

CNW Group

10 months ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

NAMS

PR Newswire

10 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

NAMS

Business Wire

10 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

NAMS

AFP

10 months ago

New Zealand scraps plan to tax livestock burps, farts

NAMS

Business Wire

10 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

NAMS

The Wall Street Journal

10 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool

NAMS

Bloomberg

10 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

NAMS

Simply Wall St.

10 months ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

NAMS

GlobeNewswire

10 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June

NAMS

GlobeNewswire

10 months ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

NAMS

GlobeNewswire

10 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)

NAMS

Simply Wall St.

a year ago

NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations

NAMS

Simply Wall St.

a year ago

NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations

NAMS

GuruFocus.com

a year ago

NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NAMS

Thomson Reuters StreetEvents

a year ago

Q4 2023 Hub Group Inc Earnings Call

NAMS

Morningstar Research

a year ago

Analyst Report: Hub Group, Inc.

Hub Group sees Q4 revenue fall 23% year-over-year to $985M

NAMS

FreightWaves

a year ago

Hub Group sees Q4 revenue fall 23% year-over-year to $985M

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

NAMS

GlobeNewswire

a year ago

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30

NAMS

CNW Group

a year ago

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

NAMS

Barrons.com

a year ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

United Arab Emirates Smart Manufacturing Market Analysis Showcases Growth Trends and Opportunities up to 2030

NAMS

GlobeNewswire

a year ago

United Arab Emirates Smart Manufacturing Market Analysis Showcases Growth Trends and Opportunities up to 2030

Hilltop Holdings Inc. (NYSE:HTH) Q4 2023 Earnings Call Transcript

NAMS

Insider Monkey

a year ago

Hilltop Holdings Inc. (NYSE:HTH) Q4 2023 Earnings Call Transcript

NAMS

Business Wire

a year ago

Sensient Announces Conference Call

AmEx 4Q profits jump 23% as cardmembers carry heftier balances

NAMS

Associated Press Finance

a year ago

AmEx 4Q profits jump 23% as cardmembers carry heftier balances

Afya Limited Announces Medical Seats Increase in FIP Guanambi

NAMS

Business Wire

a year ago

Afya Limited Announces Medical Seats Increase in FIP Guanambi

Realty Income (O) Expands With Spirit Realty Capital Merger

NAMS

Zacks

a year ago

Realty Income (O) Expands With Spirit Realty Capital Merger

Playtika (PLTK) Loses -13.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

NAMS

Zacks

a year ago

Playtika (PLTK) Loses -13.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Is Visa (V) Poised for Q1 Earnings Beat on Transactions Growth?

NAMS

Zacks

a year ago

Is Visa (V) Poised for Q1 Earnings Beat on Transactions Growth?

Director Andrew Ng Sells 75,000 Shares of Coursera Inc (COUR)

NAMS

GuruFocus.com

a year ago

Director Andrew Ng Sells 75,000 Shares of Coursera Inc (COUR)

Russell 2000 Stocks: Small Cap Chipmaker, Two Biotechs Jet Higher in Early Trade

NAMS

Investor's Business Daily

a year ago

Russell 2000 Stocks: Small Cap Chipmaker, Two Biotechs Jet Higher in Early Trade

Is Boise Cascade Company (BCC) Trading at a Compelling Valuation?

NAMS

Insider Monkey

a year ago

Is Boise Cascade Company (BCC) Trading at a Compelling Valuation?

A Look Back at Household Products Stocks' Q3 Earnings: Energizer (NYSE:ENR) Vs The Rest Of The Pack

NAMS

StockStory

a year ago

A Look Back at Household Products Stocks' Q3 Earnings: Energizer (NYSE:ENR) Vs The Rest Of The Pack

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

NAMS

Business Wire

a year ago

Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

NAMS

GlobeNewswire

a year ago

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

NAMS

PR Newswire

a year ago

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

NAMS

Zacks

a year ago

Zacks Industry Outlook Highlights Tanger and Urban Edge Properties

NewAmsterdam Pharma Announces 2024 Strategic Priorities

NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Independence Realty (IRT) Advances on Strategy With Asset Sales

NAMS

Zacks

a year ago

Independence Realty (IRT) Advances on Strategy With Asset Sales

LBRT vs. AROC: Which Stock Should Value Investors Buy Now?

NAMS

Zacks

a year ago

LBRT vs. AROC: Which Stock Should Value Investors Buy Now?

NAMS

Associated Press Finance

a year ago

Corcept Therapeutics, PNM Resources fall; Johnson & Johnson rise, Tuesday, 1/2/2024

Avangrid ends PNM acquisition bid, sees ‘no clear timing’ to resolve New Mexico PRC’s rejection of deal

NAMS

Utility Dive

a year ago

Avangrid ends PNM acquisition bid, sees ‘no clear timing’ to resolve New Mexico PRC’s rejection of deal

NAMS

Simply Wall St.

a year ago

Latest NewAmsterdam Pharma Company N.V. (NAMS) News on April 4, 2025

Share on Social Networks: